Sanofi and health technology company Aetion announced Nov. 20 a collaboration to combine their real-world evidence platforms to accelerate regulatory-grade studies and analytics of new medical treatments.
The partnership will join Sanofi's DARWIN platform with the Aetion Evidence Platform. Sanofi's platform gathers and analyzes anonymized data from millions of patients, while Aetion's analyzes real-world data to determine the effectiveness, safety and value of new drugs; together, Sanofi will be better able to develop and apply potential new treatments.
"Today marks another important step in Sanofi's digital transformation," Bernard Hamelin, MD, global head of medical evidence generation at Sanofi, said in the announcement. "By integrating these platforms, we strive to make faster, more informed decisions with the potential to lead to first-in-class and best-in-class treatments that could change the practice of medicine."
More articles on health IT:
Hyperledger welcomes 8 more members
How Apple helped inspire Stanford's new hospital & 14 other health IT notes
UPS to use sensors, data analytics, AI to track medical packages in real time